skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging

Authors:
 [1];  [2];  [1];  [2];  [2];  [2];  [3];  [2];  [2];  [2];  [2];  [2];  [2];  [2];  [2];  [2];  [2];  [2];  [2];  [3] more »;  [2];  [1];  [1];  [1];  [4];  [5];  [6];  [5];  [4];  [1];  [2];  [1] « less
  1. Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston MA 02114 USA
  2. Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road Groton CT 06340 USA
  3. Pfizer Worldwide Research and Development, 610 Main Street Cambridge MA 02139 USA
  4. Departments of Neurology & Psychiatry, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street Boston MA 02114 USA
  5. Stanley Center for Psychiatric Research, Broad Institute, 415 Main Street Cambridge MA o2142 USA
  6. Stanley Center for Psychiatric Research, Broad Institute, 415 Main Street Cambridge MA o2142 USA, Departments of Neurology & Psychiatry, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street Boston MA 02114 USA
Publication Date:
Sponsoring Org.:
USDOE
OSTI Identifier:
1401450
Grant/Contract Number:
AC02-06CH11357
Resource Type:
Journal Article: Publisher's Accepted Manuscript
Journal Name:
Angewandte Chemie
Additional Journal Information:
Journal Volume: 128; Journal Issue: 33; Related Information: CHORUS Timestamp: 2017-10-20 17:06:26; Journal ID: ISSN 0044-8249
Publisher:
Wiley Blackwell (John Wiley & Sons)
Country of Publication:
Germany
Language:
English

Citation Formats

Liang, Steven H., Chen, Jinshan Michael, Normandin, Marc D., Chang, Jeanne S., Chang, George C., Taylor, Christine K., Trapa, Patrick, Plummer, Mark S., Para, Kimberly S., Conn, Edward L., Lopresti-Morrow, Lori, Lanyon, Lorraine F., Cook, James M., Richter, Karl E. G., Nolan, Charlie E., Schachter, Joel B., Janat, Fouad, Che, Ye, Shanmugasundaram, Veerabahu, Lefker, Bruce A., Enerson, Bradley E., Livni, Elijahu, Wang, Lu, Guehl, Nicolas J., Patnaik, Debasis, Wagner, Florence F., Perlis, Roy, Holson, Edward B., Haggarty, Stephen J., El Fakhri, Georges, Kurumbail, Ravi G., and Vasdev, Neil. Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging. Germany: N. p., 2016. Web. doi:10.1002/ange.201603797.
Liang, Steven H., Chen, Jinshan Michael, Normandin, Marc D., Chang, Jeanne S., Chang, George C., Taylor, Christine K., Trapa, Patrick, Plummer, Mark S., Para, Kimberly S., Conn, Edward L., Lopresti-Morrow, Lori, Lanyon, Lorraine F., Cook, James M., Richter, Karl E. G., Nolan, Charlie E., Schachter, Joel B., Janat, Fouad, Che, Ye, Shanmugasundaram, Veerabahu, Lefker, Bruce A., Enerson, Bradley E., Livni, Elijahu, Wang, Lu, Guehl, Nicolas J., Patnaik, Debasis, Wagner, Florence F., Perlis, Roy, Holson, Edward B., Haggarty, Stephen J., El Fakhri, Georges, Kurumbail, Ravi G., & Vasdev, Neil. Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging. Germany. doi:10.1002/ange.201603797.
Liang, Steven H., Chen, Jinshan Michael, Normandin, Marc D., Chang, Jeanne S., Chang, George C., Taylor, Christine K., Trapa, Patrick, Plummer, Mark S., Para, Kimberly S., Conn, Edward L., Lopresti-Morrow, Lori, Lanyon, Lorraine F., Cook, James M., Richter, Karl E. G., Nolan, Charlie E., Schachter, Joel B., Janat, Fouad, Che, Ye, Shanmugasundaram, Veerabahu, Lefker, Bruce A., Enerson, Bradley E., Livni, Elijahu, Wang, Lu, Guehl, Nicolas J., Patnaik, Debasis, Wagner, Florence F., Perlis, Roy, Holson, Edward B., Haggarty, Stephen J., El Fakhri, Georges, Kurumbail, Ravi G., and Vasdev, Neil. 2016. "Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging". Germany. doi:10.1002/ange.201603797.
@article{osti_1401450,
title = {Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging},
author = {Liang, Steven H. and Chen, Jinshan Michael and Normandin, Marc D. and Chang, Jeanne S. and Chang, George C. and Taylor, Christine K. and Trapa, Patrick and Plummer, Mark S. and Para, Kimberly S. and Conn, Edward L. and Lopresti-Morrow, Lori and Lanyon, Lorraine F. and Cook, James M. and Richter, Karl E. G. and Nolan, Charlie E. and Schachter, Joel B. and Janat, Fouad and Che, Ye and Shanmugasundaram, Veerabahu and Lefker, Bruce A. and Enerson, Bradley E. and Livni, Elijahu and Wang, Lu and Guehl, Nicolas J. and Patnaik, Debasis and Wagner, Florence F. and Perlis, Roy and Holson, Edward B. and Haggarty, Stephen J. and El Fakhri, Georges and Kurumbail, Ravi G. and Vasdev, Neil},
abstractNote = {},
doi = {10.1002/ange.201603797},
journal = {Angewandte Chemie},
number = 33,
volume = 128,
place = {Germany},
year = 2016,
month = 6
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record at 10.1002/ange.201603797

Save / Share:
  • Cited by 7
  • A multifunctional protein kinase, purified from rat liver as ATP-citrate lyase kinase, has been identified as a glycogen synthase kinase. This kinase catalyzed incorporation of up to 1.5 mol of and)2numberSPO4/mol of synthase subunit associated with a decrease in the glycogen synthase activity ratio from 0.85 to a value of 0.15. Approximately 65-70% of the TUPO4 was incorporated into site 3 and 30-35% into site 2 as determined by reverse phase high performance liquid chromatography. This multifunctional kinase was distinguished from glycogen synthase kinase-3 on the basis of nucleotide and protein substrate specificities. Since the phosphate contents in glycogen synthasemore » of sites 3 and 2 are altered in diabetes and by insulin administration, the possible involvement of the multifunctional kinase was explored. Glycogen synthase purified from diabetic rabbits was phosphorylated in vitro by this multifunctional kinase at only 10% of the rate compared to synthase purified from control rabbits. Treatment of the diabetics with insulin restored the synthase to a form that was readily phosphorylated in vitro.« less
  • Glycogen synthase kinase-3{beta} (GSK3{beta}) is recognized as one of major kinases to phosphorylate tau in Alzheimer's disease (AD), thus lots of AD drug discoveries target GSK3{beta}. However, the inactive form of GSK3{beta} which is phosphorylated at serine-9 is increased in AD brains. This is also inconsistent with phosphorylation status of other GSK3{beta} substrates, such as {beta}-catenin and collapsin response mediator protein-2 (CRMP2) since their phosphorylation is all increased in AD brains. Thus, we addressed this paradoxical condition of AD in rat neurons treated with okadaic acid (OA) which inhibits protein phosphatase-2A (PP2A) and induces tau hyperphosphorylation and cell death. Interestingly,more » OA also induces phosphorylation of GSK3{beta} at serine-9 and other substrates including tau, {beta}-catenin and CRMP2 like in AD brains. In this context, we observed that GSK3{beta} inhibitors such as lithium chloride and 6-bromoindirubin-3'-monoxime (6-BIO) reversed those phosphorylation events and protected neurons. These data suggest that GSK3{beta} may still have its kinase activity despite increase of its phosphorylation at serine-9 in AD brains at least in PP2A-compromised conditions and that GSK3{beta} inhibitors could be a valuable drug candidate in AD.« less
  • Highlights: Black-Right-Pointing-Pointer MG132 induces the phosphorylation of GSK3{beta}{sup Ser9} and, to a lesser extent, of GSK3{beta}{sup Thr390}. Black-Right-Pointing-Pointer MG132 induces dephosphorylation of p70S6K{sup Thr389} and phosphorylation of p70S6K{sup Thr421/Ser424}. Black-Right-Pointing-Pointer Inactivation of p38 dephosphorylates GSK3{beta}{sup Ser9} and phosphorylates GSK3{beta}{sup Thr390}. Black-Right-Pointing-Pointer Inactivation of p38 phosphorylates p70S6K{sup Thr389} and increases the phosphorylation of p70S6K{sup Thr421/Ser424}. Black-Right-Pointing-Pointer Inactivation of p38 decreases autophagy and increases apoptosis induced by MG132. -- Abstract: Proteasome inhibition is a promising approach for cancer treatment; however, the underlying mechanisms involved have not been fully elucidated. Here, we show that proteasome inhibition-induced p38 mitogen-activated protein kinase regulates autophagy andmore » apoptosis by modulating the phosphorylation status of glycogen synthase kinase 3{beta} (GSK3{beta}) and 70 kDa ribosomal S6 kinase (p70S6K). The treatment of MDA-MB-231 cells with MG132 induced endoplasmic reticulum stress through the induction of ATF6a, PERK phosphorylation, and CHOP, and apoptosis through the cleavage of Bax and procaspase-3. MG132 caused the phosphorylation of GSK3{beta} at Ser{sup 9} and, to a lesser extent, Thr{sup 390}, the dephosphorylation of p70S6K at Thr{sup 389}, and the phosphorylation of p70S6K at Thr{sup 421} and Ser{sup 424}. The specific p38 inhibitor SB203080 reduced the p-GSK3{beta}{sup Ser9} and autophagy through the phosphorylation of p70S6K{sup Thr389}; however, it augmented the levels of p-ERK, p-GSK3{beta}{sup Thr390}, and p-70S6K{sup Thr421/Ser424} induced by MG132, and increased apoptotic cell death. The GSK inhibitor SB216763, but not lithium, inhibited the MG132-induced phosphorylation of p38, and the downstream signaling pathway was consistent with that in SB203580-treated cells. Taken together, our data show that proteasome inhibition regulates p38/GSK{sup Ser9}/p70S6K{sup Thr380} and ERK/GSK3{beta}{sup Thr390}/p70S6K{sup Thr421/Ser424} kinase signaling, which is involved in cell survival and cell death.« less